Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1380.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,382.0,1.0,=,3.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1963.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,731.0,1.0,=,2.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1010.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,1055.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1305.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,234.0,1.0,=,5.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1879.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,411.0,1.0,=,4.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2028.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,615.0,1.0,=,3.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,856.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,365.0,1.0,=,2.3